Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

Overview of the six original ACTIV-3/TICO trials. حسب Elizabeth S. Munroe (21568166)

"…However, there is concern that by neutralizing the SARS-CoV-2 virus, nMAbs may decrease the availability of antigens to the immune system, potentially impairing the endogenous polyclonal immune response and decreasing long-term immune protection.…"

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

Trends of prevalence (A), incidence (B) deaths (C), and DALYs (D) rates of chronic obstructive pulmonary disease per 100,000 population among adults aged ≥70 years by sex and socio... حسب Kaifang Meng (13848535)

Replication of YFV-17D cap1 and cap0 in C6/36 cells. حسب Anja vom Hemdt (19787189)

الموضوعات:

Posterior estimates of niche overlap for predators. حسب Nathan D. McTigue (10706460)

الموضوعات:

Posterior estimates of niche overlap for deposit feeders. حسب Nathan D. McTigue (10706460)

الموضوعات:

Niche overlap within shelf communities. حسب Nathan D. McTigue (10706460)

الموضوعات:

Sampling locations across the Arctic where data were aggregated. حسب Nathan D. McTigue (10706460)

الموضوعات: